The long-term effects of metformin in individuals with type 2 diabetes who are at increased risk of severe respiratory infections are unknown. This study aimed to evaluate the effects of metformin use on the risk of first pneumonia hospitalisation and pneumonia-related death in a cohort of Chinese individuals with type 2 diabetes.
We performed a retrospective analysis of a consecutive cohort of 22,638 individuals with type 2 diabetes in the Hong Kong Diabetes Register enrolled between 2001 and 2018, with follow-up until 31 December 2019. Overlap propensity-score weighting was performed to balance baseline characteristics.
Of 22,638 individuals with type 2 diabetes, after excluding those who had not been prescribed any glucose-lowering drugs (GLDs) and/or with eGFR ≤30 ml min−1 [1.73 m]−2 or treated by dialysis and/or treated with insulin at baseline, we identified 15,784 either prevalent or incident metformin users and 917 users of other GLDs during a mean follow-up period of 7.5 years. Overlap-weighted analysis showed an HR of 0.63 (95% CI 0.52, 0.77) for first pneumonia hospitalisation and 0.49 (95% CI 0.33, 0.73) for pneumonia-related death in metformin users vs users of other GLDs; similar observations resulted following stratification by sex and kidney function. There was also a negative association between metformin exposure over time (proportion of duration of metformin prescriptions during the total follow-up time) and pneumonia events using the penalised spline analysis. Metformin users had a lower neutrophil/lymphocyte ratio at first pneumonia hospitalisation vs non-metformin users (mean [95% CI]: 12.8 [12.1, 13.5] vs 14.8 [12.3, 17.3], p = 0.032). The rate of metformin-associated lactic acidosis was 2.5 per 100,000 person-years. The lower risk of pneumonia events was also observed among incident metformin users vs other GLD users.
Long-term use of metformin was associated with reduced risk of pneumonia and pneumonia-related death among Chinese individuals with diabetes. The relevance of these results to other respiratory infections merits further investigation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
The data supporting the findings of this study are available on request from the corresponding author.
Chronic kidney disease
Hong Kong Diabetes Register
Marginal structural model
Bailey CJ (2017) Metformin: historical overview. Diabetologia 60(9):1566–1576. https://doi.org/10.1007/s00125-017-4318-z
Mor A, Petersen I, Sørensen HT, Thomsen RW (2016) Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study. BMJ Open 6(8):e011523. https://doi.org/10.1136/bmjopen-2016-011523
Chan JC, Lim L-L, Luk AO et al (2019) From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care 42(11):2022–2031. https://doi.org/10.2337/dci19-0003
Cameron AR, Morrison VL, Levin D et al (2016) Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 119(5):652–665. https://doi.org/10.1161/CIRCRESAHA.116.308445
Chen X, Walther FJ, Sengers RM et al (2015) Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response. Am J Physiol Lung Cell Mol Physiol 309(3):L262–L270. https://doi.org/10.1152/ajplung.00389.2014
Pernicova I, Kelly S, Ajodha S et al (2020) Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. Lancet Diabetes Endocrinol 8(4):278–291. https://doi.org/10.1016/s2213-8587(20)30021-8
Reade M, Yende S, Angues D (2009) Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med 37(5):1655–1662. https://doi.org/10.1097/CCM.0b013e31819da853
Richy FF, Sabidó-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U (2014) Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care 37(8):2291–2295. https://doi.org/10.2337/dc14-0464
Gokhale M, Stürmer T, Buse JB (2020) Real-world evidence: the devil is in the detail. Diabetologia 63(9):1694–1705. https://doi.org/10.1007/s00125-020-05217-1
We acknowledge the Hong Kong Hospital Authority for providing the clinical data.
Authors’ relationships and activities
JCNC has received research grants and/or honoraria for consultancy and/or giving lectures from AstraZeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, Hua Medicine, Lee Powder, Merck Serono, Merck Sharp & Dohme, Pfizer and Sanofi. APSK has received research grants and/or speaker honoraria from Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli-Lilly, Merck Serono, Nestle, Novo Nordisk and Sanofi. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
AY was supported by the Impact Research Postdoctoral Fellowship of The Chinese University of Hong Kong.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yang, A., Shi, M., Wu, H. et al. Long-term metformin use and risk of pneumonia and related death in type 2 diabetes: a registry-based cohort study. Diabetologia 64, 1760–1765 (2021). https://doi.org/10.1007/s00125-021-05452-0
- Oral glucose-lowering drugs